Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the launch of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories reference laboratory network in the U.S. This innovative blood test is designed to detect cancer in older or at-risk dogs, leveraging Volition's Nucleosomics™ technology. IDEXX aims to use this test to enhance pet health and wellbeing by facilitating earlier diagnosis and treatment. With a significant potential market, this partnership is expected to expand Volition’s reach in the companion animal healthcare sector.
VolitionRx Limited (NYSE AMERICAN: VNRX) released its 2022 Business Review, highlighting significant progress as it transitions from an R&D-focused entity to one with commercial operations. Key achievements include global expansion of the Nu.Q® Vet Cancer Test, obtaining a CE mark for Nu.Q® NETs, initiating U.S. clinical product programs, and scaling operations. President Cameron Reynolds emphasized the company's advancements in epigenetics and its commitment to improving health outcomes.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported its third-quarter financial results for the period ending September 30, 2022. The company held a conference call on November 15, 2022, to discuss these results. Volition's cash and cash equivalents totaled approximately $16.4 million. The company received $6.4 million from a public offering and $1.5 million from non-dilutive funding. The Nu.Q® Vet Cancer Test launched in the U.S. and will soon be available in Europe. Volition aims to license its Nu.Q® platform and continues advancing several key clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a clinical study in collaboration with Oncovet to evaluate its Nu.Q® Vet Cancer Test in dogs and cats with cancer. Led by Dr. Jérôme Benoit, the study aims to assess the detection of various systemic cancers by measuring circulating nucleosomes. The research will involve samples from 100 dogs and 25 cats and is expected to enhance the test's applications in Europe. Previous studies indicated the Nu.Q® Vet Cancer Test detected 76% of systemic cancers with 97% specificity.
VolitionRx Limited (NYSE AMERICAN: VNRX) has been invited to join a government-backed study in France to assess blood biomarkers for early lung cancer detection, partnering with Hospices Civils de Lyon. The ILYAD study aims to evaluate Volition's Nu.Q® test in detecting lung cancer, involving over 400 subjects over the next year. Chief Commercial Officer Gael Forterre emphasized the critical need for effective lung cancer screening globally. Volition specializes in developing cost-effective blood tests using its innovative Nucleosomics™ technology.
VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q® Vet Cancer Screening Test across the U.S. and plans to expand into Europe via Heska Corporation (NASDAQ: HSKA). The test offers an accurate, affordable, and non-invasive method for early cancer detection in dogs. With approximately 84 million pet dogs in the U.S., this screening can enhance health outcomes by facilitating early treatment. This partnership aligns with Heska's growth strategy in advanced veterinary diagnostics, following a $28 million licensing agreement with Volition.
VolitionRx Limited (NYSE AMERICAN: VNRX) has signed a global supply agreement with a leading pet healthcare provider to supply the Nu.Q® Vet Cancer Test via its laboratory network. This test aims at early cancer detection in pets, particularly senior dogs, providing significant market potential given the 84 million pet dogs in the U.S. Dr. Tom Butera emphasized that this agreement helps commercialize their technology in animal healthcare. Clinical studies indicate the test can detect 76% of systemic cancers with high specificity.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.
VolitionRx Limited (NYSE: VNRX) appointed Mickie Henshall to its board of directors effective August 15, 2022. Henshall brings over 20 years of marketing experience in the IVD and life science industries, previously holding key positions at Illumina and REALM IDx. The board believes her expertise will support Volition's commercialization efforts, particularly regarding its Nu.Q® technology. Henshall noted the company's potential to revolutionize diagnostics for life-altering diseases. Volition is focused on developing cost-effective blood tests for monitoring diseases, including cancer.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its second-quarter financial results for the period ending June 30, 2022. The company reported cash and cash equivalents of approximately $16.7 million, down from $20.6 million at year-end 2021. However, they secured $6.4 million via a public offering post-quarter and received $1.5 million in non-dilutive funding. Volition has made strides with the CE Mark for its Nu.Q® NETs test in Europe and is expanding clinical studies in the U.S. with MD Anderson and Diagnostic Oncology CRO LLC, aiming for FDA clearance in 2023.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
